A Phase 4 interventional study of Oral Cholera Vaccine and Adjusted Dose Oral Cholera Vaccine in Cholera and Vibrio Cholerae Infection, sponsored by Johns Hopkins Bloomberg School of Public Health. Completed at 1 site in Zambia. Open to participants aged 1 Year and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-04-05.
Sponsored by Johns Hopkins Bloomberg School of Public Health · Phase 4, Interventional, and Prevention
Cholera is a life-threatening disease if prompt actions are not taken. The most recent estimates of the global burden of cholera estimate that there are more than 1.3 billion people at risk. Of which, 2.86 million (range: 1.3-4.0 million) will contract cholera and 95,000 (21,000-143,000) will die each year. A safe, effective, and affordable killed whole-cell oral cholera vaccine (OCV) is now being used widely to prevent cholera in areas at risk. This regimen demonstrated 65% efficacy retained for at least 3 years and even up to 5 years in an endemic setting.
The primary aim of this project is to determine changes in the vibriocidal geometric mean titers (GMT) in subjects who receive the second dose of oral cholera vaccine (OCV) at different intervals: 2 weeks, or 6 months following the first dose of vaccine. Secondary aims include a) vibriocidal antibody response rates in subjects who receive OCV at 2 weeks or 6 months following the first dose of vaccine, b) age specific serum vibriocidal GMTs following the second dose among participants given the second dose of OCV at intervals of 2 weeks or 6 months following the first dose of vaccine, c) GMT and antibody response rates of Immunoglobulin A (IgA) and Immunoglobulin G (IgG) anti-lipopolysaccharide (anti-LPS) as measured by ELISA following the second dose among participants given the second dose of OCV at intervals of 2 weeks or 6 months following the first dose of vaccine. Our hypothesis is that the vibriocidal GMT following the second dose, when given after 6 months will not be inferior to the response when the second dose is given according to the standard interval of two weeks.
Cholera is a life-threatening disease if prompt actions are not taken. The most recent estimates of the global burden of cholera estimate that there are more than 1.3 billion people at risk. Of which, 2.86 million (range: 1.3-4.0 million) will contract cholera and 95,000 (21,000-143,000) will die each year. A safe, effective, and affordable killed whole-cell oral cholera vaccine (OCV) is now being used widely to prevent cholera in areas at risk. This regimen demonstrated 65% efficacy retained for at least 3 years and even up to 5 years in an endemic setting.
As described in the package insert, the standard dosing schedule of the OCV is two doses with the second dose given 2 weeks after the first. In several campaigns, it was felt to appropriate to give a single dose to twice as many people and to give the second dose at a later time when this was logistically possible. In fact, modelling of the impact of OCV during an outbreak finds that when the vaccine supply is limited (as it is currently), more cases are prevented if a single dose strategy is used since a single dose can be provided to twice as many people. Even if the efficacy is a bit lower, the number of cases prevented will be higher. Even the individual person in this situation will be better off if more of his neighbors also receive vaccine since he benefits from the herd protection when more people are vaccinated.
A single dose strategy was used during an outbreak in Zambia in 2015-16, but this first dose was then followed up with a second dose after 6 to 8 months. I was also used in Haiti in 2016-17 following the hurricane. While the delayed second dose strategy has been used and will likely continue to be used during outbreaks or during humanitarian crises, there is no feasible way to assess the relative effectiveness against clinical cholera comparing a two-week interval with a delayed second dose strategy.
While clinical effectiveness trials are not feasible, serological responses comparing different dose intervals are possible. One such study found that vibriocidal titers were similar if the second dose was given either 2 week or 4 weeks after the first , but studies have not been done with longer dose intervals, as was used in Zambia and Haiti.
The proposed study will determine if giving the second dose of the OCV using a longer interval will result in a response to the second dose that is not inferior, or perhaps even results in a more prolonged elevated vibriocidal titre. From an immunological standpoint, there could be advantages to a longer dose interval if this resulted in a true booster response which sustained high titre of antibody. While acknowledging that the vibriocidal titer is not an established correlate of protection, it is the best correlate of the immune response following vaccination. It seems logical that a sustained high titer is likely to be more effective. Unfortunately, the clinical trials comparing the 2 week and 4 week interval with Shanchol only examined the serum titers shortly after the dosing (about 2 weeks). Follow-up serum samples were not obtained to discern how these dose intervals compared in terms of duration of elevated serum titres.
Recent studies have found that children \<5 years of age are less well protected than older individuals even though their serum antibody response rates (take rates) were similar to the older subjects when the serum was collected about two weeks after the vaccine doses were administered. These immunogenicity studies have not, however, examined antibody titers when blood samples were obtained after a longer time interval. Therefore, it is not known if the antibody titers decline at the same rate as older subjects. It could be that GMT titers are lower or that titers fall more rapidly in the young children, and a different dosing interval could maintain higher titres. To compare antibody responses in different age groups, we plan to stratify groups into age 1-4, 5-14, and 15 years and older.
83 studies on the registry are indexed under Cholera; 16 are open to participants now.
This study's enrollment of 120 is below the median of 262 across 72 interventional studies indexed under Cholera.
Browse Cholera studies →Johns Hopkins Bloomberg School of Public Health is the lead sponsor of 371 studies on the registry; 42 are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 3 (60%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants in Dose-Interval Group 1 (DIG-1) will receive the oral cholera vaccine, Shanchol, according to the manufacturer instructions: in 2 doses at Day 0 and two weeks later (Day 14).
Biological: Oral Cholera Vaccine
Participants in Dose-Interval Group 2 (DIG-2) will receive the Adjusted Dose oral cholera vaccine, Shanchol, with a delayed second dose. The vaccine will be given at Day 0 and six months later.
Biological: Adjusted Dose Oral Cholera Vaccine
Shanchol is a bivalent (O1 and O139 serotypes) vaccine using a heat-killed classical Inaba strain and a formalin-killed classical Ogawa strain produced by Sanofi. Shanchol requires no oral buffer for administration, is approved for persons greater than 1 year of age, and requires 2 doses at two-week intervals. It became World Health Organization (WHO) prequalified in 2011.
Also known as: Shanchol
The Adjusted Dose Oral Cholera Vaccine is given in two doses, with the second dose given at six months, rather than the manufacturer described 2 week interval between first and second dose.
Also known as: Shanchol delayed dose
Change in Vibriocidal GMT
The primary aim of this project is to determine changes in the vibriocidal geometric mean titers (GMT) in subjects who receive the second dose of oral cholera vaccine (OCV) at different intervals: 2 weeks or 6 months following the first dose of vaccine.
Time frame: 6 months
Vibriocidal Antibody Response Rates
vibriocidal antibody response rates in subjects who receive OCV at 2 weeks or 6 months following the first dose of vaccine.
Time frame: 2 weeks and 6 months
Age specific vibriocidal response
age specific serum vibriocidal GMTs following the second dose among participants given the second dose of OCV at intervals of 2 weeks or 6 months months following the first dose of vaccine.
Time frame: 2 weeks and 6 months
IgG ELISA Antibody Response
GMT and antibody response rates of IgG anti-LPS as measured by ELISA following the second dose among participants given the second dose of OCV at intervals of 2 weeks or 6 months following the first dose of vaccine.
Time frame: 2 weeks and 6 months
IgA ELISA Antibody Response
GMT and antibody response rates of IgA anti-LPS as measured by ELISA following the second dose among participants given the second dose of OCV at intervals of 2 weeks or 6 months following the first dose of vaccine.
Time frame: 2 weeks and 6 months
This study is completed, as verified in Apr 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Johns Hopkins Bloomberg School of Public Health →